$HUM

Humana soars, Alignment plummets in 2027 Medicare Advantage star ratings

Humana's Medicare Advantage star ratings improved significantly in 2027, with 93% of its members in 4+ star plans, up from 41% in 2026. This could generate $3B+ in extra revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, with only 25% of members in 4+ star plans in 2027, down from 98%. The CMS methodology changes made it harder for insurers to achieve higher ratings, with the average star rating falling to 3.99.

Original reporting
Published Oct 9, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana soars, Alignment plummets in 2027 Medicare Advantage star ratings — source image
Decision brief

The 30-second read

$HUMBullishHigh
01

Why it matters

Humana's star rating surge is a rare positive catalyst for a large insurer, while Alignment's downgrade signals a sizable revenue hit.

02

Market read

Humana's stock rallied on the news; Alignment's shares fell sharply, highlighting rating‑driven market moves within the MA space.

03

What to watch

Potential litigation by Alignment and other MA carriers may create regulatory risk that could affect peer valuations.

Relevance 9/10Novelty 8/10Timing: postmarket Thursday

Background

Medicare Advantage star ratings directly affect bonus payments and plan competitiveness; CMS adjusted methodology for 2027, making higher stars harder to achieve.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Humana's 2027 Medicare Advantage star rating jumps to 93% in 4+ star plans, potentially adding $3B+ revenue and driving a 13% post‑market stock surge.

Expected impact

upward pressure as investors price in the $3B+ revenue boost from higher star ratings

Evidence & confidence

The star rating improvement is a material, first‑report catalyst for a large‑cap insurer with a sizable revenue impact and immediate price reaction.

Market effects

Medicare Advantage sector may see rating‑driven revenue shifts, rewarding insurers that improve star scores and penalizing those that fall below thresholds.

U.S. health‑care insurers, especially MA players, could experience valuation adjustments.

Limited to U.S. health‑care markets; no direct global spillover.

Counterpoint

The rating boost could be short‑lived if CMS tightens methodology further, making the revenue upside uncertain.

Key entities

  • Humana

    Second‑largest Medicare Advantage insurer, ticker HUM.

  • Alignment Healthcare

    California‑based Medicare Advantage insurer facing star rating downgrade.

Related articles

$HUMHighAI 8/10

Humana Stock Surges 14% as Medicare Ratings Hit CVS Health

Humana's stock rose 14% after its Medicare Advantage plans saw a significant improvement in quality ratings, with 95% of members in 4-star or higher plans for 2027. This could bring $3.6B in additional revenue. CVS Health's Aetna saw a decline in ratings, with 69% of members in 4-star or higher plans, down from 81%.

$HUMHighAI 8/10

Humana surges after emerging as top beneficiary of 2027 Medicare star ratings

Humana's shares rose 15% premarket after analysts identified it as the top beneficiary of 2027 Medicare star ratings. 95% of its Medicare Advantage members will be in plans rated 4 stars or higher, up from 20% in 2026. Analysts expected 60-70%. Higher ratings lead to government bonus payments and boost enrollment. Humana's ratings outperform larger rivals like UnitedHealth and CVS Health, according to J.P. Morgan.